Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
175.8 EUR | +2.36% | +2.99% | +22.03% |
Jun. 11 | Merck KGaA to Build EUR62 Million Facility for Life Science Business | MT |
Jun. 07 | Health Care Up as Defensive Rotation Continues - Health Care Roundup | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm trades with high earnings multiples: 24.98 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.79 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.03% | 80.12B | A | ||
+13.63% | 9.18B | A- | ||
+48.35% | 4.67B | - | ||
-20.52% | 4.56B | A- | ||
+7.99% | 4.11B | B- | ||
+9.54% | 2.24B | B | ||
-25.72% | 2.2B | C- | ||
+12.16% | 2.11B | - | - | |
-41.98% | 1.85B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA